News
Hosted on MSN4mon
MSD makes licence agreement with Hengrui Pharma for Lp(a) inhibitorMSD will pay Hengrui Pharma $200m upfront, up to $1.77bn in development, regulatory and commercial milestones, and royalties on net sales.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback